- Home
- MGYR vs ANL Comparison
MGYR vs ANL Comparison
Compare MGYR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGYR
- ANL
- Stock Information
- Founded
- MGYR 1922
- ANL 2004
- Country
- MGYR United States
- ANL Cayman Islands
- Employees
- MGYR N/A
- ANL N/A
- Industry
- MGYR Savings Institutions
- ANL
- Sector
- MGYR Finance
- ANL
- Exchange
- MGYR Nasdaq
- ANL Nasdaq
- Market Cap
- MGYR 91.4M
- ANL 73.8M
- IPO Year
- MGYR 2006
- ANL 2023
- Fundamental
- Price
- MGYR $15.90
- ANL $1.82
- Analyst Decision
- MGYR
- ANL Strong Buy
- Analyst Count
- MGYR 0
- ANL 2
- Target Price
- MGYR N/A
- ANL $9.00
- AVG Volume (30 Days)
- MGYR 8.3K
- ANL 10.1K
- Earning Date
- MGYR 07-24-2025
- ANL 06-10-2025
- Dividend Yield
- MGYR 1.64%
- ANL N/A
- EPS Growth
- MGYR 19.38
- ANL N/A
- EPS
- MGYR 1.43
- ANL N/A
- Revenue
- MGYR $34,067,000.00
- ANL N/A
- Revenue This Year
- MGYR N/A
- ANL N/A
- Revenue Next Year
- MGYR N/A
- ANL N/A
- P/E Ratio
- MGYR $11.12
- ANL N/A
- Revenue Growth
- MGYR 12.12
- ANL N/A
- 52 Week Low
- MGYR $10.66
- ANL $1.10
- 52 Week High
- MGYR $16.00
- ANL $8.88
- Technical
- Relative Strength Index (RSI)
- MGYR 71.22
- ANL 45.00
- Support Level
- MGYR $15.22
- ANL $1.71
- Resistance Level
- MGYR $15.51
- ANL $2.10
- Average True Range (ATR)
- MGYR 0.32
- ANL 0.09
- MACD
- MGYR 0.07
- ANL 0.01
- Stochastic Oscillator
- MGYR 93.75
- ANL 28.21
About MGYR Magyar Bancorp Inc.
Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.